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Abstract
Globally, the microbe Neisseria gonorrhoeae (NG) causes 106 million newly documented sexually 
transmitted infections each year. Once appropriately diagnosed, NG infections can be readily 
treated with antibiotics, but high-risk patients often do not return to the clinic for treatment if 
results are not provided at the point of care. A rapid, sensitive molecular diagnostic would help 
increase NG treatment and reduce the prevalence of this sexually transmitted disease. Here, we 
report on the design and development of a rapid, highly sensitive, paperfluidic device for point-of-
care diagnosis of NG. The device integrates patient swab sample lysis, nucleic acid extraction, 
thermophilic helicase-dependent amplification (tHDA), an internal amplification control (NGIC), 
and visual lateral flow detection within an 80 min run time. Limits of NG detection for the NG/
NGIC multiplex tHDA assay were determined within the device, and clinical performance was 
validated retroactively against qPCR-quantified patient samples in a proof-of-concept study. This 
paperfluidic diagnostic has a clinically relevant limit of detection of 500 NG cells per device with 
analytical sensitivity down to 10 NG cells per device. In triplicate testing of 40 total urethral and 
vaginal swab samples, the device had 95% overall sensitivity and 100% specificity, approaching 
current laboratory-based molecular NG diagnostics. This diagnostic platform could increase 
access to accurate NG diagnoses to those most in need.
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1 Introduction
Sexually transmitted infections (STIs) caused by Neisseria gonorrhoeae (NG) account for 
106 million newly documented STI cases each year (World Health Organization 2012). In 
low-resource settings, many NG infections remain untreated, both because they can remain 
asymptomatic for years and because rapid and sensitive diagnostics are still lacking (Aledort 
et al. 2006; Bourgeois et al. 1998; World Health Organization 2007). Untreated gonorrhea 
infections can cause pelvic inflammatory disease, infertility, and ectopic pregnancy among 
women, and additional complications via neonatal transmission. NG infections also facilitate 
HIV transmission (Aledort et al. 2006; Fleming and Wasserheit 1999); people with NG 
infections are up to five times more likely to contract HIV (Wasserheit 1992), and are three 
times more likely to transmit HIV to someone else (Fleming and Wasserheit 1999). Once 
diagnosed, this serious but treatable infection is often cured with a one-time dose of 
appropriate antibiotics. However, diagnosis through current state-of-the-art methods, such as 
swab sample culturing or PCR, require an equipped laboratory, trained staff, and several 
days or even weeks to complete.
Due to long turnaround times, patients often fail to return for laboratory diagnostic results 
and follow up treatment. As a result, the United States Centers for Disease Control urges 
clinics to use point-of-care (POC) tests to ensure that high-risk patients receive treatment in 
the same visit (Johnson et al. 2002). Despite some progress in developing immunoassay 
based rapid diagnostic tests (RDTs) and near-patient qPCR systems, a POC NG diagnostic 
that combines high specificity and sensitivity with low-cost is not yet available (Gaydos et 
al. 2013; Greer and Wendel 2008; Guy et al. 2017). While manufacturer reported 
sensitivities are as high as 98.3% for both urethral and vaginal swab samples (Huppert et al. 
2010; Cortez 2006), clinical studies comparing multiple RDTs to qRT-PCR have shown 
RDT sensitivities of only 54% for vaginal swab samples (Alary et al. 2006). If timely results 
are available, much more sensitive nucleic acid amplification tests (NAATs) are still 
recommended over immunologic RDTs (Johnson et al. 2002; Papp et al. 2014).
In this work, we present an integrated system that bridges that gap between RDTs and 
laboratory-based NAATs. Our POC NG diagnostic device features integrated sample 
preparation, DNA amplification, and lateral flow strip (LFS) detection. We have previously 
developed a portable and inexpensive paperfluidic Human Papilloma Virus (HPV) 
diagnostic device composed of only of porous paper membranes and adhesive plastic 
(Rodriguez et al. 2016). Here, we expand the platform to NG and enhance clinical reliability 
by incorporating an internal amplification control to differentiate between negative test 
results and invalid tests, a feature that will inevitably be required for regulatory approval of 
POC NAATs (Johnson et al. 2002; U.S. Food and Drug Administration 2011; Lafleur et al. 
2016). In our NG diagnostic, cells in patient urethral and vaginal samples are added to lysis 
buffer which is then washed through a porous polyethersulfone (PES) substrate to precipitate 
and concentrate sample DNA. Excess fluid is wicked away to a removable waste pad. NG 
DNA and internal control DNA (NGIC) are then amplified in a multiplexed isothermal, 
thermophilic helicase-dependent amplification (tHDA) reaction. The resulting molecular 
probe-labeled amplicons flow to an integrated LFS for simple visual detection. We evaluated 
the analytical sensitivity by determining the limit of detection, the selectivity against 29 
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bacterial and viral strains that can also colonize the genital tract, and performed a small pilot 
study using 40 retrospective clinical samples to establish repeatability and clinical diagnostic 
metrics of the test.
2 Methods
2.1 DNA Stocks, Cell Stocks
NG strain NCTC 8375 (ATCC, Manassas, VA) was grown on chocolate agar in 5% CO2 at 
37 °C for 24–36 h. Genomic NG DNAwas harvested from cultured cells by incubating 
colonies in 10% sodium dodecyl sulfate in 5 M guanidinum thiocya-nate followed by 
phenol:chloroform DNA extraction and ethanol precipitation (Dillard 2011). DNA was then 
quantified via Nanodrop. Nucleic acids isolated from 29 co-inhabitant commensal and 
pathogenic microbes of the genital tract were supplied from the Johns Hopkins Center for 
the Development of Point of Care Tests for Sexually Transmitted Diseases at Johns Hopkins 
University (JHU).
2.2 Clinical Samples
Previously de-identified, discard clinical samples collected at JHU were used in the 
retrospective study containing a total of 40 vaginal and urethral patient swab samples with 
10 NG positive and 10 NG negative specimens of each sample type. These were collected 
and used in accordance with Institutional Review Board (IRB) protocols approved by Boston 
University and JHU. The diagnostic status of the samples was previously determined at JHU 
by using a laboratory NAAT, the MagNA-pure extraction and qPCR system (Roche 
Molecular Systems, Pleasanton, CA). Vaginal swabs were qPCR tested with a duplicate 
swab from the same de-identified patient sample, while urethral swabs were initially tested 
and then reused in our study. Swabs were stored dry at −80 °C until sample processing. 
Samples were processed by thawing the swabs for 2 min at room temperature and then 
placing them into 150 μL of sterile water in a 1.7 mL tube. The tubes were vortexed for 30 s, 
and the reconstituted sample was aliquoted and refrozen at −80 °C for later device 
application and DNA extraction.
2.3 qPCR Confirmation of Human and NG DNA in Clinical Samples
DNAwas extracted from reconstituted patient samples using a column-based Qiagen Blood 
and Tissue kit (Qiagen Corporation, Hilden, Germany). Following DNA extraction, DNA 
integrity was confirmed by detection of the human RNAseP housekeeping gene and NG 
genomic loads were quantified via SureStart Taq polymerase (Agilent, Santa Clara, CA) 
qPCR per manufacturer’s instructions on a QuantStudio5 Real-Time PCR system (Thermo 
Scientific, Waltham, MA). Primers and probes listed in Table S1 were purchased from 
Integrated DNA Technologies (Coralville, IA). Samples were heated to 95 °C for 10 min 
followed by 45 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 15 s.
2.4 tHDA Assay
Previously confirmed as PES compatible (Linnes et al. 2016), our tHDA assay amplifies the 
highly conserved and single-copy porA pseudogene, which is specific to the NG genome 
(Unemo et al. 2005). Like any molecular target, mutations of the porA gene could result in 
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false-negative results test results. However, recent antimicrobial resistance studies have 
shown that porA mutants represented less than 0.4% of clinical NG isolates (Toby et al. 
2017). Primer sequences and assay components, originally designed by Biohelix Inc. 
(Quidel Corporation, San Diego, CA), are listed in Table S1. In tube tHDA assays were 
performed for 30 min at 65 °C via the QuantStudio5 thermocycler. The internal 
amplification control, NGIC, is an engineered plasmid that uses the same amplification 
primers as the target NG porA pseudogene but has a different molecular probe sequence, 
enabling differential detection. NG/NGIC tHDA multiplexing was optimized through 
titration (data not shown), and all subsequent tHDA reactions contained 104 spiked in copies 
of NGIC plasmid. Successful amplification of NG and NGIC targets was confirmed via gel 
electrophoresis as well as detection of amplicon-probe complexes on the LFS. Selective 
amplification of the NG porA pseudogene and NGIC was confirmed by sequencing gel 
extraction products.
2.5 Lateral Flow Strip Detection
Commercial LFS were purchased from Ustar Biotechnologies (Hangzhou, China). NG 
probes were labeled with fluoresce-in isothiocyanate (FITC) while NGIC probes were 
tagged with digoxigenin (DIG) for detection on LFS via anti-DIG and anti-FITC stripes, 
respectively. LFS band intensities were imaged and quantified using ImageJ (NIH, Bethesda, 
MD) and objectively assessed via threshold-based densitometry, where NG and NGIC band 
intensities were compared to the LFS background.
2.6 Paperfluidic Device Fabrication
The 30 mm × 30 mm reaction housing contained an 8.5 mm circular hole as the center 
reaction chamber and was fabricated from 6 layers of 188 μm thick cyclic olefin polymer 
(Zeon Chemicals, L.P., Louisville KY) with a GraphTec CE6000–40 cutting plotter. A 9.5 
mm diameter punch of a 0.22 μm pore size PES membrane (EMD Millipore, Billerica, MA) 
was placed between the two bottom layers. The chip was bonded together with a heat press 
as previously described (Roy et al. 2012). A waste pad laser-cut from Whatman #3 paper 
(Sigma Aldrich, St Louis, MO), and a commercial LFS with fluorescein isothiocyanate 
(FITC), digigoxin (DIG), and streptavidin detection lines (#D005–05, Ustar 
Biotechnologies, Hangzhou China) were attached using 3 mm thick self-adhesive plastic 
(Fellowes, Itasca, IL). Adhesive reaction chamber lids were aligned using pre-marked ‘X’s 
on the device housing tabs and re-covered to prevent contamination. Completed chips were 
stored in a sterile container until use.
2.7 Integrated On-Chip Assay
On-chip DNA precipitation, washing, amplification, and LFS detection were modified from 
the protocol of Rodriguez et al. (2016) and performed using 5 μL of DNA-containing 
samples added to 95 μL of guanidinium thiocyanate lysis/DNA precipitation buffer with 
NGIC plasmid (Fig. 1). In addition to using COP reaction housing instead of adhesive, 
modifications included adding 15 μL of mineral oil to increase heat transfer efficiency, as 
well as incubating the tHDA reaction on a heat block at 65 °C for 45 min under a Styrofoam 
insulator. After adding 60 μL of commercially supplied LFS running buffer, the detection 
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and control lines on the attached LFS were read within 5 min. Acrylamide gel analysis of 
heated reactions additionally confirmed amplification.
2.8 Statistical Analysis
Dunnet’s multiple comparison test was used to calculate the limit of detection using 
GraphPad Prism software. The limit of detection was determined to be the lowest NG DNA 
concentration input into the assay that resulted in a statistically significant difference (p < 
0.05) from the no DNA control as detected by LFS. In-tube assays were run with nine 
replicates at each NG concentration while paperfluidic device assays were run with six 
replicates per NG concentration tested. Device and benchtop reactions with neither NG nor 
NGIC LFS lines were discarded from analysis due to failed tHDA, and reactions with no 
LFS lines were discarded for faulty flow conditions. Chips with weak NGIC or flow control 
lines but strong NG lines were included in analysis, as positive NG detection was still 
observed (Gervais and Delamarche 2009).
Using the positive and negative patient samples as a comparative test set, we determined the 
paperfludic device’s preliminary diagnostic sensitivity and specificity. Three device trials per 
patient sample were used to assess repeatability and results were binned together. We used 
stringent requirements that all three-device results be concordant with the JHU qPCR 
reference standard in order to be considered a true positive or true negative as detailed in the 
results.
3 Results
We optimized the tHDA assay to detect NG and NGIC in both a tube and integrated device 
format. Using a NGIC concentration of 104 copies per reaction, the multiplex tube assay 
detected 100 genomic copies per reaction (Table 1) with statistical significance compared to 
the negative, no template control (p < 0.05). Further, in some replicates, the assay was 
capable of detecting as few as 10 genomic copies per reaction (Fig. 2).
When transferred to the device, the limit of NG detection was 500 genomic NG copies (p < 
0.05 compared to negative control), with digital amplification down to 10 genomic copies 
per device (Table 1, Fig. 3). The slightly poorer detection may have been caused by partial 
sample recovery during DNA precipitation or by tHDA amplification inhibition. 
Amplification inhibition can be the result of residual lysis and precipitation buffer 
components, device materials, or a reduction in reaction heating efficiency. However, the 
device detection limit was still well above expected patient sample bacterial loads (Priest et 
al. 2017; Lowe and Kraus 1976). The frequency of device failure in our limit of detection 
study was 4%; only 2 out of 50 chips tested failed to amplify either NG or NGIC targets.
To confirm assay selectivity for the NG-specific porA pseudogene, we tested our 
multiplexed tHDA assay against range of potential confounding microbes. These selectivity 
tests found no cross-species amplification within any of the 29 bacterial and viral genomes 
tested in our NG and NG/NGIC multiplex tHDA assays (Table S2). These results confirm 
our assay’s selectivity towards NG DNA amplification. Selectivity for NG and NGIC was 
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further confirmed by sequencing the amplification products generated from genomic NG 
and NGIC plasmid tHDA reactions (data not shown).
Having demonstrated assay selectivity and a clinically relevant device limit of detection for 
NG in our integrated device, we next determined the expected NG bacterial load in clinical 
urethral and vaginal swab samples (Table S3). No NG DNA was detected in any of the NG-
negative swabs. In the NG-positive patient samples, qPCR quantification of patient sample 
DNA extracts showed an average of 6.59*104 porA pseudogene copies per swab (range: 
1.56*102 to 2.41*105) across the NG-positive urethral swab isolates and an estimated 
average of 2.86*106 copies per swab (range: 3.56*102 to 1.87*107) over the NG-positive 
vaginal swab isolates. Using these qPCR values, the approximate average NG DNA 
concentrations input into the device were 2.53*103 organisms per urethral swab and 
1.81*105 organisms per vaginal swab.
To maximize the evaluation of device reproducibility, we tested each clinical sample in three 
separate devices. Overall conditions for successful amplification were present in 88% (53 
out of 60) of the tests performed on vaginal samples and in 92% (55 out of 60) of the tests 
performed on urethral samples (Table S3). Device trials were only considered correlative 
with the JHU standard if all three of the trials concurred with the reference standard. Our 
paperfluidic device repeatedly detected NG DNA from reconstituted swabs across all three 
device trials in 9 out of 10 NG-positive urethral swab samples and in 10 out of 10 NG-
positive vaginal swabs (Table S3). Additionally, we saw no false positive NG detection in 
replicate tests of the 10 negative vaginal and 10 negative urethral swab samples.
4 DISCUSSION
In this proof-of-concept study, we developed a low-cost paperfluidic device for detection of 
NG DNA from urethral and vaginal samples. Device run time approaches suitability for the 
clinical point of care at 80 min turnaround time from sample-to-result. In the tHDA limit of 
detection studies, there is a slight reduction in the device detection limit compared to in-tube 
experiments, however, both methods were able to detect as few as 10 copies of DNA in a 
subset of reactions. Further development of this platform will focus on reducing the 
turnaround time from 80 min to less than 60 min and decreasing the required user interaction 
to fewer than three steps in order to align it with the recently published target produce 
profile for point-of-care NG diagnostic tests (Toskin et al. 2017). Presently, patient sample 
processing and reaction chamber drying require 30 min, amplification requires 45 min, and 
LFS interpretation another 5 min. To reduce device run time and amplification success, we 
are optimizing reaction chamber drying and tHDA efficiency.
The lower detection limit of 500 genomic NG copies per reaction in our device is sensitive 
enough to detect infections in both urethral swabs (Priest et al. 2017) and vaginal samples 
(Lowe and Kraus 1976). Of note, some apparent qPCR estimates of bacterial loads fell 
below our projected limit of detection (e.g., NG positive urethral samples #2, 3, 6, and 9 
(Table S3)). We hypothesize that the extraction efficiency of the membrane-based 
precipitation used in the device may have actually been better than the silica-based 
commercial kit used to prepare our qPCR swab samples. Membrane-based precipitation has 
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been shown to be effective at even low concentrations of DNA, while previous reports have 
shown significant genomic DNA losses from silica-based kits at DNA concentrations below 
104 CFU/mL (Kulinski et al. 2009). We saw a reduced bacterial load in our qPCR 
measurements when comparing our urethral swab NG bacterial load quantifications to a 
previous study (Priest et al. 2017). While extraction efficiency may play a role in this 
reduction, the urethral swabs we received had already been used for initial diagnostic testing 
and some material was certainly removed during this process.
By testing 29 bacterial and viral species that commonly inhabit human genitalia (Brotman 
2011; Price et al. 2010; Linnes et al. 2014) with the tHDA multiplex assay, we screened for 
non-specific amplification even with high DNA genomic loads under optimal amplification 
conditions. Assay selectivity was confirmed, as none of the potentially confounding targets 
amplified.
An important characteristic of all diagnostic test development is the evaluation of replicate 
trials of the same sample in different devices. We performed critical experiments to ensure 
clinical device reliability by evaluating multiple device trials in our limit of detection as well 
as patient sample validation studies. In patient sample trials, we performed 120 total device 
trials with the 40 clinical samples (triplicate tests for each sample). Conditions for successful 
amplification were present in 88% of the vaginal samples and in 92% of the urethral 
samples. All invalid tests arose in the NG negative samples due to assay conditions that were 
unfavorable for NGIC amplification. Inclusion of NGIC enabled this important 
differentiation between false negative results, and failed amplification conditions. When 
comparing to the 96% success rate of the pre-isolated NG DNA trials, the lowered success 
of NGIC amplification in NG-negative swab device trials suggests that both urethral and 
vaginal patient sample matrices introduce some inhibition to amplification. Indeed, this has 
been seen in other recent paperfluidic NAATs, which had a 62% success rate of 
Staphylococcus aureus detection using clinical nasal samples (Lafleur et al. 2016). To 
improve our device success rate in future trials with NG negative patient samples, NGIC 
amplification will require further optimization, such as adjusting assay salt balance and 
ensuring complete washing for removal of the patient sample matrices.
The United States Food and Drug Administration currently advises that rapid NG NAAT 
diagnostics in development should reach 95% sensitivity and 95% specificity (U.S. Food and 
Drug Administration 2011). A more recent target product profile developed by international 
STI experts indicated that 90% sensitivity and 90% specificity would be acceptable for 
surveillance and screening in a test that required less than 60 min (Toskin et al. 2017). A 
limitation to our pilot study is that the sample size is underpowered to determine true 
diagnostic sensitivity and specificity of the paperfluidic device. We would have required 146 
clinical samples for 95% sensitivity and 95% specificity measurements (or 279 samples for 
90% sensitivity and 90% specificity) using a prevalence of 50%, confidence level of 95%, 
and accuracy of 0.05. Nevertheless, in our 40-sample study, 19 of the 20 NG positive 
samples amplified and no false positives were detected in the 20 NG negative samples. 
These promising results indicate the targeted clinical diagnostic sensitivity and specificity 
are feasible with a larger sample size. As our device reliability trials illustrated diagnostic 
disparity in only 1 out of the 40 patient samples, likely due to NG concentrations near the 
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assay limit of detection, future validation studies could be performed with a single device 
per sample with minimal adverse impact on sensitivity and specificity. These future 
validation trials will include a larger sample size using blinded samples of fresh, 
prospectively collected swabs from patients with both asymptomatic and symptomatic NG 
infections.
5 CONCLUSIONS
Our device yielded a statistically significant lower detection limit of 500 genomic NG copies 
per reaction, digital detection from as few as 10 NG copies, which resulted in an assay that 
is sensitive enough to detect infections in clinical urethral and vaginal swabs. We validated 
the device in a rigorous proof-of-concept study using forty discarded de-identified urethral 
and vaginal swabs, each tested in three separate device trials. Our device had an overall 
sensitivity of 95% (detecting 19 of 20 positive samples) and specificity of 100% for all 
sample types. These promising results are an exciting proof-of-principle demonstration for 
this POC NG NAAT platform. The further development of this diagnostic platform could 
overcome many NG testing barriers currently faced in limited-resource settings and increase 
access to accurate NG diagnoses for those most in need.
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Fig. 1. 
Workflow for NG precipitation, amplification, and detection within a low-cost paperfluidic 
device. Before device application, 5 μL of patient sample is pipetted and mixed with 95 μL 
of lysis/precipitation buffer. The precipitant mix is then applied to the reaction chamber of 
the device via pipette (a). After washing the reaction chamber with 70% and 95% ethanol, 
the lateral flow strip (LFS) is folded over and the waste pad is torn off and discarded (b). 
After drying, mineral oil is added to the smaller reaction chamber cavity and sealed with a 
tab (c, yellow) and tHDA amplification mix including NGIC is added to the larger cavity 
and sealed (c, green). The LFS is folded over top of the mineral oil side of the device before 
the device is heated on a standard hot plate underneath a Styrofoam insulator (d). Following 
heating, the tab sealing the tHDA mix is removed, allowing the LFS sample pad to touch the 
reaction chamber and LFS running buffer is applied to the end of the LFS (e) to enable 
visual detection of amplification results (f, photo g)
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Fig. 2. 
To determine the multiplex tHDA assay’s limit of NG detection, serially diluted genomic 
NG DNA was amplified in a thermocycler and analyzed via gel electrophoresis (top) and 
LFS threshold densitometry (bottom). Representative reactions for each concentration are 
illustrated here. The lowest concentration of NG DNA that yielded statistically significant 
amplification versus the negative control (p < 0.05, N = 9 for each condition) is considered 
the assay’s limit of NG detection (red asterisk)
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Fig. 3. 
Limit of NG DNA detection with the NG/NGIC tHDA multiplex assay in the paperfluidic 
device. To determine the paperfluidic device’s limit of NG detection, serially diluted 
genomic NG DNA was amplified under the device protocol (Fig. 1). Reactions extracted 
from the devices were analyzed via gel electrophoresis (top) and LFS threshold densitometry 
(bottom). Representative device reactions for each concentration are illustrated here. The 
lowest concentration of DNA that yielded statistically significant amplification success 
compared to the no NG DNA controls (N = 6 for each condition) is considered the limit of 
NG detection for the device (red asterisk). In these studies, the frequency of device success 
was 96%
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Table 1
Comparison of tHDA multiplex amplification in optimal heating conditions via thermocycler and in the 
paperfluidic device
tHDA Heating Conditions Genomic NG copies per reaction
0 101 5*101 102 5*102 103 5*103 104 105
Positive NG amplification in thermocycler (n = 9) 0% 33% 56% 78%* 100%* 100%* 100%* 100%* 100%*
Positive NG amplification in device (n = 6) 0% 17% 17% 33% 83%* 100%* 100%* 100%* 100%*
All reactions contained 104 copies of NGIC plasmid per reaction. Bold underlined values designate the limit of detection and
*indicates p < 0.05 versus the no NG (0 copy) control using Dunnett’s multiple comparison test.
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